Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Karen Champenois, Maison Blanche Hospital, Paris
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Karen Champenois, Maison Blanche Hospital, Paris
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Cary James, Terrence Higgins Trust
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Phillip Keen (Kirby Institute) discusses the successes and challenges of community-based HIV testing.
This presentation was given at the AFAO National HIV Forum, 17 October 2014.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Tonio Piscopo, Mater dei Hospital
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Cary James, Terrence Higgins Trust
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Phillip Keen (Kirby Institute) discusses the successes and challenges of community-based HIV testing.
This presentation was given at the AFAO National HIV Forum, 17 October 2014.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Tonio Piscopo, Mater dei Hospital
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Amanda Mocroft, UCL
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
A Decade of Behavioral HIV Prevention and Care Engagement Research in Uganda: Responding to Evolving Epidemic Response Priorities
Susan M. Kiene, PhD, MPH
March 2nd, 2018
UCSD HIV & Global Health Rounds
Screening for syphilis as part of HIV monitoring increases detection of early, asymptomatic syphilis among HIV positive homosexual men. Presentation given by Marcus Chen at the AFAO National Syphilis Forum, 23 October 2009.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey. Presented by Mark Gilbert, BC CDC, at the 5th Annual Gay Men's Health Summit held in Vancouver, BC on November 9th and 10th, 2009.
The Flu-FIT Program : An Effective Colorectal Cancer Screening Intervention
Présentation de Michael B. Potter au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Антиретровирусное лечение – перспективы Европейского клинического общества по...hivlifeinfo
Антиретровирусное лечение – перспективы Европейского клинического общества по СПИДу (EACS)/Antiretroviral Treatment.The European AIDS Clinical Society (EACS) Perspective.2017
Men's Health & Primary Care: Improving Access and OutcomesMen's Health Forum
Presentation made to the EMHF Primary Care Roundtable about men's health and primary care access - including usage of the internet for health purposes - England - July 2, 2014
Victorian HIV Service STI Project: How simple is to ordering a blood test? Presentation given by Brian Price at the AFAO National Syphilis Forum, 23 October 2009.
Comparative Effectiveness of a Multifaceted Intervention to Improve Adherence to Annual Colorectal Cancer Screening in Community Health Centers (RCT)
Présentation de David W. Baker au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Where's the hope? Dialogues for Solidarity - Session 4ReShape
This session explored current work experiences in HIV care from a specialist point of view and looked at how current conditions impacted related care providers. Reflecting on the changing nature of HIV care and the changing needs of people living with HIV, the session examined the policy implications of a fragmented system and the patients' perspective on HIV care.
The Care Providers session was expected to lay the groundwork for a future session on the failing Health Economy as a leading issue.
Where's the hope? Dialogues for Solidarity - Session 1ReShape
Session 1: GIPA Principles for the 21st Century with guest, Sean Strub, Sero Project, USA
Where’s the Hope?, a year-long series of dialogues for solidarity, is coordinated by ReShape, an independent London-based think tank formed to respond to the ongoing crisis in sexual health.
Working together, activists and organisers will share their experiences and explore new op- portunities to address explore chronic obstacles to successful organising in HIV, HCV and re- lated sexual and mental health concerns. Emerging advocates and organisers are especially welcome.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. bcn checkpoint
V I H - S I D A ▪ I T S ▪ S E X U A L I T A T ▪ H O M E S ▪ S A L U T
Results and Next Steps
Michael Meulbroek
Projecte dels NOMS-Hispanosida
Challenges and opportunities for community testing centres
Barcelona, 5 October de 2014
3. Results
2007 2008 2009 2010 2011 2012 2013
1. Number of tests 1.065 1.228 2.485 3.425 3.837 5.051 5.062
2. Persons tested 903 1.124 2.201 2.896 3.198 4.049 4.030
3. HIV positive 37 72 113 126 132 138 138
4. % HIV positive 4,1% 6,4% 5,1% 4,4% 4,1% 3,4% 3,4%
5. Persons at first visit BCN Checkpoint 850 957 1.583 1.722 1.689 1.717 1.682
6. HIV positive at first visit 36 53 91 100 90 92 78
7. % HIV positive at first visit 4,2% 5,5% 5,7% 5,8% 5,3% 5,4% 4,6%
4. Impact of BCN Checkpoint
2007 2008 2009 2010 2011 2012
2013 *
(Prov.)
1. Number of tests 1.098 1.272 2.483 3.453 3.962 5.051 5.062
2. Persons tested 951 1.162 2.197 2.896 3.198 4.049 4.030
3. HIV positive 37 72 113 126 132 138 138
8. Total HIV cases in MSM reported in
Catalonia
319 300 280 360 374 430 357
9. % of cases detected in
BCN Checkpoint
11,6% 24,0% 40,4% 35,0% 35,3% 32,1% 38,7%
* Data Ceeiscat 3rd October 2014
5. Early detection
• 31% of the new HIV cases detected in BCN Checkpoint are recent
infections (< 6 months)
• 57% of the new cases are infections < 12 months
6. Linkage to HIV unit (2009-2013)
665 persons
HIV reactive tests
633 persons
HIV reactive tests
562 persons
linked to care
14 previously HIV positive
71 persons
non-linked
24 persons returned
to country of origin
18 false positive
33 persons
Excluded:
self-linked to care
88,8%
14 persons
lost
2,2% 3,8% 5,2%
8. Results Check-ear (2009-2014)
Prevalence higher than in
the general population
• 250 participants
• 16% prevalence asymptomatic STIs at
baseline (1/6)
• Gonorrhea (rectum 5,6% / penis 2,0%)
• Chlamydia (rectum 6,3% / penis 3,1%)
9. Results Check-ear (2009-2014)
Alternative effector-function profiling
identifies broad HIV-specific T-cell
responses in highly HIV-exposed
individuals who remain uninfected.
Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreño J, Yusim
K, Bach V, Mothe B, Perez-Alvarez S, Fernandez MA,
Requena G, Meulbroek M, Pujol F, Leon A, Cobarsi P,
Korber BT, Clotet B, Ganoza C, Sanchez J, Coll J,
Brander C.
Journal Infectious Diseases 2014 Sep 23. pii: jiu534
10. Next Steps
Implementation of new services:
Syphilis, Chlamydia, Gonorrhea and HCV testing
Hepatitis A and B vaccination
11. The ÍTACA Cohort
(December 2008 – December 2013)
8.165 participants - 4.481 persons with follow-up visit
223 infections HIV
Incidence HIV: 2,43 x 100 persons/year
(95% CI: 2,13 – 2,77)
General population: incidence = 0,02%
12. Match prediction with reality?
Prevalence and Awareness of HIV Infection Among Men Who Have Sex With Men —
21 Cities, United States, 2008 (MMWR, Sept. 24, 2010, 59(37) 1201-7)
Ronald Stall, PhD. Best Practices in HIV
Prevention: Translating Innovation into
Action. Boston, September 27, 2013
13. Next Steps
So, we know what means an high HIV incidence…
What are the behavior surveys we need?
“HIV is increasing among MSM not because of greater risk-taking
behavior, but simply because HIV is so prevalent among their sex partners
that even one or two slip-ups can have devastating consequences.”
Susan Buchbinder
FDA Advisory Committee for PrEP approval
10th May 2012
14. The effectiveness of condoms is limited / has peaked
Uso del preservativo
Siempre 714 56,3%
Casi siempre 476 37,5%
A veces 34 2,7%
Casi nunca 15 1,2%
Nunca 17 1,3%
No contesta 13 1,0%
Total 1,269
Estudio Ítaca - BCN Checkpoint (2008-2011)
93,8%
15. What can reduce HIV incidence?
A. Phillips. MSM in the UK: Prevention Effects of ART in Perspective. 21st CROI, Boston, abstract 116, 2014